JBJ-02-112-05 is a highly potent, mutant-specific, allosteric and orally bioavailable EGFR inhibitor with an IC50 of 15 nM for EGFRL858R/T790M. References: [1]. To C, et al. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discov. 2019 Jul;9(7):926-943.

纯度：≥98%